CHM CDH17 Phase 1 clinical trial update - New DL 3 data
Filed with ASX · · 6 pages · English
Summary by 6ix AI
The interim results show promising signs of anti-tumor activity, with tumor shrinkage observed in individual lesions and stable disease maintained in some patients for several months. The company has treated four patients at this dose level and plans to continue monitoring their progress while preparing to treat additional patients. This announcement reflects ongoing developments in the trial, which aims to evaluate the safety and efficacy of a novel CAR-T cell therapy for advanced gastrointestinal cancers.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Appointment of Financial Adviser for Strategic Review
- CHM announces positive Phase 1/2 data at ASCO
- Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
- Consolidation/Split - CHM
- Chimeric receives $1.8 M advance on FY26 R&D tax incentive
Later from Chimeric Therapeutics
- Chimeric receives $1.62M advance on FY26 R&D tax incentive
- CHM ceases enrolment in Phase 1 trial and Company update
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics